# Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer

> **NCT07731607** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Wang Jianliu** · enrollment: 48 (estimated)

## Conditions studied

- MMRd Endometrial Cancer of Stage I~II

## Interventions

- **DRUG:** Sintilimab monotherapy

## Key facts

- **NCT ID:** NCT07731607
- **Lead sponsor:** Wang Jianliu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2030-07-20
- **Final completion:** 2030-07-20
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07731607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07731607, "Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07731607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*